Mike, my best answer is for you to just read the SEC filings.
The following is factual and I suggest you go ahead and verify it.
Radient is currently in default of over $18 million in loans. The lenders have the right to convert the debt at 58% of the current share price so they can get their shares at less that anyone else can.
The sales of Onko Sure was $56,000 in the last reported quarter of 2011. That is the last financial filing Radient has made.
There are only two employees left, the CEO and CFO and they are unpaid. Radient uses three former employees as contract workers to just manufacture tests for their remaining sales.
The last reported filing stated that they had just enough refined antibody to make 200 more kits. It is unknown if they have the money to refine more antibody or if they have made less than 200 kits.
One of the two patents they have for Onko Sure has expired and the last one expires in 15 months. A Chinese company has began sales of generic kits and their sales rep stated that they did not have any conection with Radient that she was aware of.
Provista nor GCDS is not interested in buying Radient nor did they continue the licensing of DR-70 after they had received all the information on manufacturing the test.
In a recent email to an investor, MacLellan stated that production of Onko Sure has recently been increased but he did not mention any numbers for sales at all.
MacLellan is known for not telling the truth. He is in fact being sued for that reason.
Buy at your own risk but do not ever think this company will survive or have any real value. The Onko Sure product has been around for over 25 years, failed in a launch attempt in 2001 and is doing no better today. The reason it failed in 2001 was a bad reputation for false positives. Nothing has changed to decrease the number of false positives.
News 
Market Data 
Discover 
